Table 1.

Clinical and laboratory data of patients with SSc showing elevated serum PTX3 levels. Unless noted otherwise, values are percentages.

CharacteristicElevated PTX3, n = 38Normal PTX3, n = 53
No. male/female5/335/48
Age at onset, mean ± SD yrs48 ± 1646 ± 14
Disease duration, mean ± SD yrs5.5 ± 6.75.8 ± 7.3
Disease pattern, no. dSSc/ISSc23/1522/31
Clinical features
  Modified Rodnan TSS, mean ± SD17.3 ± 8.6*10.8 ± 6.1
  Pitting scar/ulcer5840
  Diffuse pigmentation5349
  Contracture of phalanges58*26
Organ involvement
  Lungs
    Pulmonary fibrosis63**34
    % VC, mean ± SD83.7 ± 23.8*99.5 ± 22.0
    % DLCO, mean ± SD52.6 ± 15.8*65.5 ± 16.2
    Pulmonary hypertension138
  Esophagus7468
  Heart29*9
  Kidneys34
  Joints2121
  Muscles1319
Laboratory findings
  Positive for anti-topoisomerase I Ab53*30
  Positive for anti-RNP Ab86
  Positive for anticentromere Ab3248
  Serum IgG, mean ± SD mg/dl1895 ± 603**1522 ± 441
  Serum IgA, mean ± SD mg/dl365 ± 163*286 ± 110
  Serum IgM, mean ± SD mg/dl198 ± 107211 ± 140
  CRP, mean ± SD mg/dl0.21 ± 0.350.25 ± 0.43
  ESR, mean ± SD mm/h20.8 ± 11.6*14.8 ± 15.3

  • ESR: erythrocyte sedimentation rates, TSS: total skin thickness score, VC: vital capacity, Ab: antibody, CRP: C-reactive protein.

  • ↵* p < 0.05,

  • ↵** p < 0.01 versus SSc patients with normal serum PTX3 levels.